ABOS - CIK 0001576885
The table below shows Acumen Pharmaceuticals, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $104.89M | $93.80M | $42.32M | $32.36M | $12.30M | $8.00M |
| SG&A | $18.95M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $20.22M |
| $18.82M |
| $12.88M |
| $7.28M |
| $1.35M |
| Operating income | -$123.83M | -$114.02M | -$61.14M | -$45.24M | -$19.58M | -$7.91M |
| Income tax | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$121.33M | -$102.33M | -$52.37M | -$42.86M | -$100.61M | -$7.33M |
| EPS (diluted) | -$2.00 | -$1.71 | -$1.08 | -$1.06 | -$5.02 | - |